Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (FIND-CKD)

This study has been completed.
Luitpold Pharmaceuticals
ICON Clinical Research
Information provided by (Responsible Party):
Vifor Inc. Identifier:
First received: October 12, 2009
Last updated: May 9, 2014
Last verified: May 2014
Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).

Condition Intervention Phase
Iron Deficiency Anaemia
Chronic Kidney Disease
Drug: FCM (Ferric carboxymaltose) high ferritin target
Drug: FCM (Ferric carboxymaltose) low ferritin target
Drug: Oral Iron (Ferrous sulphate)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-label, Multicentre, Randomised, 3-arm Study to Investigate the Comparative Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject High and Low Dosage Regimens) Versus Oral Iron for the Treatment of Iron Deficiency Anaemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease

Resource links provided by NLM:

Further study details as provided by Vifor Inc.:

Primary Outcome Measures:
  • Kaplan-Meier Survival Analysis for Time to Other Anemia Therapy or Hb Trigger [ Time Frame: Up to 1 year after baseline ]

    Endpoint reported number of participants with/without events and was reached:

    • First time of initiation of additional or alternative anaemia management,
    • First time the subject reached the Hb trigger.

      3 primary comparisons using a hierarchical step-down procedure on the log-rank test to preserve an alpha level of 0.05, performed in the following order:

      1. FCM (high ferritin target) compared with oral iron.
      2. FCM (high ferritin target) compared with FCM (low ferritin target).
      3. FCM (low ferritin target) compared with oral iron.

    Sensitivity analyses of the primary endpoint were performed using the following alternative definitions of time to initiation of additional or alternative anaemia management:

    1. Without taking into account the Hb trigger.
    2. Taking into account the Hb trigger based on local laboratory data, instead of central laboratory data.
    3. Taking into account the Hb trigger based on subjects with a complete set of Hb values from the central laboratory.

Enrollment: 626
Study Start Date: December 2009
Study Completion Date: February 2014
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: FCM (high ferritin target)
Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 400 - 600 mcg/L
Drug: FCM (Ferric carboxymaltose) high ferritin target
Other Names:
  • Ferinject
  • Injectafer
Experimental: FCM (low ferritin target)
Ferric carboxymaltose (FCM) (Ferinject / Injectafer) targeting ferritin level of 100 - 200 mcg/L
Drug: FCM (Ferric carboxymaltose) low ferritin target
Other Names:
  • Ferinject
  • Injectafer
Active Comparator: Oral Iron
Ferrous sulphate 100 mg iron twice daily, continuous
Drug: Oral Iron (Ferrous sulphate)
Other Name: Ferrous sulphate

Detailed Description:

After an initial screening period of up to 4 weeks, eligible subjects were randomised (1:1:2) to 1 of the following 3 treatment arms for a period of 52 weeks.

  1. FCM regimen (maximum single intravenous doses of 1,000 mg of iron) targeting a ferritin level of 400-600 mcg/L.
  2. FCM regimen (maximum single intravenous doses of 200 mg of iron) targeting a ferritin level of 100-200 mcg/L.
  3. Daily oral iron with 200 mg iron/day (100 mg twice daily)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. At least 18 years of age.
  2. NDD-CKD subjects with an estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73 m2 using modification of diet in renal disease 4 (MDRD-4) calculation.
  3. NDD-CKD subjects with an eGFR loss ≤12 mL/min/1.73 m2/year and a predicted eGFR of ≥15 mL/min/1.73 m2 in 12 months.
  4. Any single Hb between 9 and 11 g/dL within 4 weeks of randomisation. A value taken as part of routine medical care was used.
  5. Any single serum ferritin <100 mcg/L or <200 mcg/L with TSAT <20% within 4 weeks of randomisation. Measurements taken as part of routine medical care were used.
  6. ESA naïve; no exposure to ESA in last 4 months prior to randomisation.
  7. Females of childbearing potential must have had a negative pregnancy test, using any medically acceptable assessment, prior to randomisation.
  8. Before any study specific procedure, the appropriate written informed consent must have been obtained.

Exclusion Criteria:

  1. History of acquired iron overload.
  2. Known hypersensitivity reaction to any component of ferrous sulphate or FCM. Subjects with hypersensitivity to other forms of iron were permitted to participate.
  3. Documented history of discontinuing oral iron products due to significant gastrointestinal (GI) distress.
  4. Screening TSAT >40%.
  5. Known active infection, C-reactive protein >20 mg/L, clinically significant overt bleeding, active malignancy (i.e., clinical evidence of current malignancy or not in stable remission for at least 5 years since completion of last treatment with exception of basal cell or squamous cell carcinoma of the skin, and cervical intraepithelial neoplasia).
  6. History of chronic alcohol abuse (alcohol consumption >40 g/day).
  7. Chronic liver disease and/or screening alanine transaminase or aspartate transaminase above 3 times the upper limit of the normal range.
  8. Active human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome or active hepatitis B or C virus infection.
  9. Anaemia due to reasons other than iron deficiency (e.g., haemoglobinopathy). Subjects with treated Vitamin B12 or folic acid deficiency were permitted.
  10. IV iron and/or blood transfusion in previous 30 days prior to screening (or during the screening period).
  11. Oral iron therapy at doses >100 mg/day dosing must have been discontinued at least 1 week prior to randomisation. If subject had received this therapy for >3 months (at doses >100 mg/day) then subject was not eligible. Ongoing use of multivitamins containing iron was permitted.
  12. Immunosuppressive therapy that may have led to anaemia (e.g., cyclophosphamide, azathioprine, or mycophenolate mofetil). Steroid therapy was permitted.
  13. Currently requiring renal dialysis.
  14. Anticipated dialysis or transplant during the study.
  15. Anticipated need for surgery that may have resulted in significant bleeding (>100 mL).
  16. Currently suffering from chronic heart failure New York Heart Association Class IV.
  17. Poorly controlled hypertension (>160 mmHg systolic pressure or >100 mmHg diastolic pressure).
  18. Acute coronary syndrome or stroke within the 3 months prior to screening.
  19. Currently suffering from concomitant, severe psychiatric disorders or other conditions which, in the opinion of the Investigator, would have made participation unacceptable.
  20. Subject was not using adequate contraceptive precautions.
  21. Subject of childbearing potential was evidently pregnant (e.g., positive human chorionic gonadotropin test) or was breast feeding.
  22. Body weight <35 kg.
  23. Subject currently was enrolled in or had not yet completed at least 30 days since ending other investigational device or drug studies, or subject was receiving other investigational agent(s).
  24. Subject would not be available for follow-up assessment.
  25. Subject had any kind of disorder that compromised the ability of the subject to give written informed consent and/or to comply with study procedures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00994318

  Show 19 Study Locations
Sponsors and Collaborators
Vifor Inc.
Luitpold Pharmaceuticals
ICON Clinical Research
Principal Investigator: Iain Macdougall King's College Hospital NHS Trust
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Vifor Inc. Identifier: NCT00994318     History of Changes
Other Study ID Numbers: FER-CKD-01
Study First Received: October 12, 2009
Results First Received: April 4, 2014
Last Updated: May 9, 2014

Keywords provided by Vifor Inc.:
Ferinject Iron Deficiency Anaemia Chronic Kidney Disease

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Anemia, Iron-Deficiency
Deficiency Diseases
Hematologic Diseases
Urologic Diseases
Renal Insufficiency
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Nutrition Disorders
Ferric Compounds
Trace Elements
Growth Substances
Physiological Effects of Drugs
Hematinics processed this record on May 22, 2017